
Foreword
On October 15, a Korean client delegation visited Anhui Poly Pharmaceutical Co., Ltd. to conduct an on-site inspection and business discussions centered on BPA (Boron [10B] Phenylalanine API). Mr. Li of Anhui Poly and relevant business leaders received the visiting team. The two parties held in-depth exchanges on topics including product quality standards, supply chain assurance, international regulatory collaboration, and cooperation on next-generation innovative boron drug pipelines, jointly exploring pathways for international collaboration in the BNCT boron drug field.
PART 01
Mutual Technical Trust: Building on an Internationalized Quality System to Strengthen the Industrial Foundation for Boron Drug Innovation
Anhui Poly provided the Korean client with a comprehensive overview of the company's development, with a focus on its global strategic layout for BNCT boron drugs. In addition to its mature independently industrialized Boron [10B] Phenylalanine API—achieving raw material purity ≥99.9% and 10B abundance ≥99%—the company also presented to the visiting client its complete BNCT innovative drug R&D platform. Breaking through the limitations of traditional BPA targets, the platform encompasses multiple differentiated pipelines under development, including metabolism-targeted small molecules and BDC boron-conjugated drugs, forming a complete technology matrix combining mature products with original innovation.

As an enterprise deeply engaged in the international pharmaceutical arena, the company has established a comprehensive quality management system benchmarked against the world's highest standards and continues to advance the overseas translation of its boron drug innovations. The visiting Korean client introduced its regional market demand and long-term cooperation vision. The two parties fully exchanged views on stable BPA supply, multinational regulatory support, joint development of innovative pipelines, and directions for sustainable strategic cooperation, establishing deep mutual trust at the technical level.

PART 02
On-Site Verification: Field Audit of the Internationalized cGMP System, Demonstrating the Hard Strength of APIs
The Korean client successively visited the company's QC laboratory and API production site. In the QC laboratory, the client conducted a detailed investigation of the full-process testing protocols for BPA and the internationalized quality control system; in the production workshop, they observed on site the equipment operation and maintenance, process control, and shop-floor management standards.


The client gave positive feedback on Anhui Poly's cGMP quality management system, which is aligned with European and American standards, and on its standardized production capabilities. Anhui Poly adheres to an internationalized system as its foundation, constraining the entire R&D and production chain with global regulatory standards. This not only ensures the stable export of existing APIs but also lays a solid production and quality foundation for the global industrialization of subsequent innovative boron drugs, supporting the output of innovative APIs to global markets.

PART 03
Cooperation Outlook: Deepening Transnational Exchange, Positive Progress in BPA Cooperation Negotiations

Following the on-site visits and multiple rounds of technical and business discussions, the Korean client expressed high recognition of Anhui Poly's BPA product quality and continuous supply capability, and the two parties reached a preliminary cooperation intention regarding the BPA business.
Leveraging the strong product strength of its BPA API and comprehensive international registration capabilities, Poly's boron drugs have successfully achieved overseas market entry. This transnational exchange has created favorable conditions for BNCT boron drugs to further expand into the East Asian market and represents an important milestone in the globalization layout of Poly's boron drugs.

As the core API production base under Hainan Poly Pharm, Anhui Poly has achieved independent mass production of Boron [10B] Phenylalanine API. The product has had a Drug Master File (DMF) submitted to the US FDA (DMF No.: 44131), achieving internationalization of the product variety. With BPA mass production, annual capacity can reach 500 kg, enabling stable supply to global clinical, research, and formulation companies with no supply gaps.
Hainan Poly Pharm consistently adheres to an innovation-driven internationalization path. While consolidating the overseas expansion of its existing APIs and formulations, the company continues to advance the R&D and global layout of next-generation targeted boron drugs such as PL009 and PL012, as well as BDC boron-conjugated drugs, driving the overseas expansion of China's independently developed BNCT boron drug technologies and helping domestically developed innovative APIs benefit cancer patients worldwide.
Inquiries and international cooperation discussions are welcome!
Business contact:lisubin@hnpoly.com
PART 04
About Anhui Poly

Anhui Poly Pharm. Co., Ltd., founded in 2018, is located in the Anqing National High-Tech Industrial Development Zone. It is a professional supplier of active pharmaceutical ingredients (APIs), providing high-quality specialty raw materials to the global pharmaceutical, healthcare, and skincare industries through chemical synthesis and biotechnological synthesis.
Anhui Poly boasts a strong and highly efficient R&D and production team, is equipped with modern production facilities, and has established a rigorous EU/US high-end API cGMP quality system and a high-standard EHS system. While supplying customers with high-quality APIs and intermediates, the company also offers CDMO services and process technology upgrades. At present, the company has 3 API production workshops compliant with EU, US, and Chinese GMP standards, 10 production lines, and 357 pieces of multi-functional equipment.
Leveraging its strong R&D capabilities and technology transfer expertise, the company has completed the commercial R&D and production of a series of products, including contrast agents (Gadoteric acid meglumine, Gadoteridol, Gadobutrol, Iomeprol, Iopromide, Iohexol, Iopamidol, Iodixanol, etc.), synthetic biology products (Semaglutide, Ectoine, Salidroside), antitumor APIs (Cyclophosphamide), other APIs (Magnesium Hydroxide, Apremilast, Crisaborole, Voriconazole, Memantine Hydrochloride), and other pharmaceutical excipients (DOTA, SNAC, Sulfobutyl-β-cyclodextrin sodium, Calcitetracemate calcium, Cobiprostone calcium).
Since its establishment, Anhui Poly has repeatedly passed official inspections by mainstream international regulatory agencies such as those of China and the United States, and its quality management system's stability and continuous improvement capabilities have been widely recognized.
Disclaimer & Forward-Looking Statement
This article is intended solely for the purposes of pharmaceutical science popularization and corporate information introduction. Its content integrates publicly disclosed materials and summaries of the company's R&D progress and is for reference only. Statements in this article concerning drugs and projects do not constitute medical diagnosis or treatment advice, nor investment advice, nor do they promise any future outcomes. Cooperation arrangements such as contract manufacturing and API supply require the completion of quality system establishment and compliant registration, and are ultimately subject to approval by regulatory authorities. The data and views contained herein are based on publicly available information as of the date of publication of this article, and the company assumes no obligation to continuously update them.
Forward-looking statements in this article concerning regulatory filings, market planning, business development, and the like are all made based on existing information and reasonable assumptions and are subject to uncertainty. Affected by various risk factors such as market conditions and industry policies, actual circumstances may differ materially from expectations. The company has no obligation to revise the relevant content due to subsequent changes. Readers are kindly requested to fully understand the risks and exercise prudent judgment.
